News
CTMX
--
0.00%
--
BRIEF-Cytomx Therapeutics Posts QTRLY Net Loss Per Share, Basic And Diluted $0.30
reuters.com · 33m ago
BRIEF-Cytomx Therapeutics Inc Files For Mixed Shelf Of Upto $250 Million
reuters.com · 52m ago
CytomX EPS in-line, misses on revenue
CytomX (NASDAQ:CTMX): Q2 GAAP EPS of -$0.30 in-line. Revenue of $16.29M (-1.9% Y/Y) misses by $0.67M. Press Release
Seekingalpha · 1h ago
-- Earnings Flash (CTMX) CYTOMX THERAPEUTICS Posts Q2 Revenue $16M, vs. Street Est of $17M
MT Newswires · 5h ago
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)
Benzinga · 9h ago
BRIEF-CytomX Therapeutics Announces Multiple Publications On Pacmilimab (CX-072)
reuters.com · 1d ago
CytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1)
-Translational whole-body PET clinical imaging supports conditional activation in the tumor microenvironment-
GlobeNewswire · 1d ago
CytomX Therapeutics to Present at Upcoming August Investor Conferences
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody(R) technology platform, today announced tha...
GlobeNewswire · 3d ago
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.
Benzinga · 4d ago
CytomX Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody technology platform, today announced that it will re...
GlobeNewswire · 07/29 12:00
CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Should You Buy?
Zacks.com · 07/29 04:36
Anavex (AVXL) to Report Q3 Earning: What's in the Cards?
Zacks.com · 07/27 17:24
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26)
Benzinga · 07/27 11:48
Stocks That Hit 52-Week Lows On Monday
    Monday morning saw 115 companies set new 52-week lows.
Benzinga · 07/26 14:09
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20)
Benzinga · 07/21 11:52
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19)
Benzinga · 07/20 12:19
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)
Benzinga · 07/16 11:37
Here's Why CytomX Therapeutics (CTMX) is Poised for a Turnaround After Losing 15.8% in 4 Weeks
Zacks.com · 07/14 14:00
The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13)
Benzinga · 07/14 11:48
Webull provides a variety of real-time CTMX stock news. You can receive the latest news about CytomX through multiple platforms. This information may help you make smarter investment decisions.
About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.